ArticleJournal of clinical microbiology2026
Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration.
Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cefiderocol Susceptibility in Japanese Clinical Enterobacterales Isolates and the Effect of IMP-Type Carbapenemases on Resistance.Antibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefiderocol (FDC) is a siderophore cephalosporin approved for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (MDR-GNB), including carbapenem-resistant (CR) isolates. However, interpretation criteria for both broth microdilution (BMD) and disk diffusion (DD) methods differ among Clinical and Laboratory Standards Institute (CLSI), European Committee on Antimicrobial Susceptibility Testing (EUCAST), and U.S. Food and Drug Administration (FDA) guidelines. This study aimed to assess the categorical agreement (CA) between minimum inhibitory concentrations (MICs) determined by the BMD method and inhibition zone diameters measured by the DD method for FDC, using different interpretive breakpoints across various Gram-negative bacilli (GNB) isolates. A total of 1,170 GNB isolates were collected, including CR and carbapenem-susceptible (CS) isolates of IMPORTANCE: Cefiderocol is one of the few remaining treatment options for infections caused by carbapenem-resistant Gram-negative bacilli (GNB). Accurate interpretation of susceptibility testing is essential for guiding effective therapy. However, discrepancies among breakpoints established by the Clinical and Laboratory Standards Institute, the European Committee on Antimicrobial Susceptibility Testing, and the U.S. Food and Drug Administration may result in inconsistent interpretations, particularly when using the disk diffusion (DD) method, which is more practical in many clinical laboratories. This study compares the categorical agreement between broth microdilution and DD method interpretations for Gram-negative bacilli across multiple guidelines and highlights the potential for misclassification. It also provides susceptibility data for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.